ArticleQuantitative imaging in medicine and surgery2026
The study on cerebral variations and cognitive function in male patients with hyperuricemia using amide proton transfer imaging.
Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hyperuricemia is a significant health concern, but its link to cognitive function remains unclear, with limited neuroimaging evidence. This cross-sectional study used amide proton transfer (APT) imaging to investigate brain variations in male hyperuricemic patients (HUA), including those with gout, and evaluate their correlations with cognition. Methods: Twenty-five male patients with hyperuricemia (14 asymptomatic and 11 with gout history) and 25 healthy controls (HC) were prospectively recruited. All participants underwent serum uric acid (SUA) testing, cognitive assessments [Montreal Cognitive Assessment (MoCA), Mini-Mental State Examination (MMSE)], and 3T magnetic resonance imaging (MRI) including APT-weighted imaging with B0 correction. APT-weighted (APTw) values (MTRasym at 3.5 ppm) were quantified in 21 brain regions using a standardized, blinded protocol. Group comparisons (independent t-tests) and partial correlation analyses [controlling for age, education, body mass index (BMI), and SUA] were performed with false discovery rate (FDR) correction. Results: Significant differences were observed in SUA levels (HUA Conclusions: APT-MRI detected widespread alterations in APTw signal across multiple brain regions in HUA. These alterations, particularly in the left hippocampus and bilateral caudate nuclei, were associated with poorer cognitive performance on the MMSE, suggesting a potential neuroimaging biomarker for hyperuricemia-related cognitive changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.